Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Out RUBI @ $2.00 -- sure would have liked to have been able to trade pre-market. A lot of profit-taking now.
RUBI
Out of ADT at the end of the day @ $10.30 for a loss. Didn't want to be in for earnings. Didn't exit fast enough as went from ~ .50 to .30 in a matter of minutes; had been .68 earlier in the day. Hope to get back in after earnings dust settles.
ADT
Thanks for the message. Was weighing their quarterly results and the announcement which I knew was this month and I felt strongly would be positive. My E-trade account doesn't allow extra hours trading so bailed. You did great by holding. Will eventually get back in since this company is currently undervalued. BUT, hate the way MMs trade throughout the day -- very frustrating. Do you watch their shenanigans or put it on the back burner?
ALT
Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient population
Objective response rate (ORR) for follicular lymphoma patients treated with G100 and pembrolizumab combination therapy increased to 54%, with a 75% ORR in the subset of TLR4-high patients
SEATTLE and SOUTH SAN FRANCISCO, March 12, 2018 (GLOBE NEWSWIRE) --
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced updated data from two separate trials evaluating its lead product candidates, CMB305 and G100. CMB305 is a novel prime-boost immunotherapy targeting NY-ESO-1+ cancers, and G100 is a novel synthetic TLR4 agonist for intratumoral immunotherapy. Evidence of clinical benefit continued to mature with both agents, providing not only further support for the advancement of both programs, but also supporting the view that an immunotherapy may provide additional clinical benefit with time.
Data Update from the CMB305 Monotherapy Trial
Immune Design initially presented data at the American Society of Clinical Oncology 2017 Annual Meeting from 25 NY-ESO-1+ soft tissue (STS) patients, including 14 synovial sarcoma patients. The median follow up at the time was 11.4 months, in a patient population where 92% had relapsed or refractory metastatic disease, 52% had received ≥2 lines of chemotherapy, and 56% had actively progressing disease at study entry, an unfavorable prognostic factor.
As of the time of the most recent data analysis, median follow up of patients was 17.7 months. Observations are as follows:
• Median overall survival (OS) across all STS patients has been reached at 23.7 months. The median OS for the subset of synovial sarcoma patients, the targeted patient population in the company’s planned Phase 3 trial, has still not yet been reached.
These survival data compare favorably to the reported median OS for approved second line and later agents, which are only 12.4-13.5 months for STS patients, and 11.7 months for synovial sarcoma patients specifically.
• Patients who develop an anti-NY-ESO-1 immune response on CMB305 therapy have better survival.
• CMB305 continues to be well tolerated, with only one Grade 3 adverse event.
Data Update from G100 and pembrolizumab Randomized Phase 2 Combination Trial
Immune Design initially presented data at the 2017 American Society of Hematology Annual Meeting (ASH 2017) from a randomized Phase 2 trial of 26 follicular lymphoma patients, pursuant to a collaboration with Merck. Patients were randomized evenly to one of two treatment arms: G100 with fractionated, low-dose radiation (XRT) or G100+XRT with pembrolizumab combination therapy. The data have matured as of the most recent data analysis, with observations as follows:
• Additional responses have been observed in the combination arm (54% ORR, compared to a 15% ORR in the G100+XRT arm). This is an improvement from the ASH 2017 data, which showed an ORR of 39% in the combination arm.
• The patient population with high TLR4 expression in the tumor continue to receive greater benefit, with an updated 75% ORR on the combination arm (6/8 patients), an increase from the 57% ORR reported at ASH 2017.
These data compare favorably to pembrolizumab monotherapy presented at ASH 2017, which showed an 11% ORR in a separate follicular lymphoma study.
• 77% of patients in the combination arm experienced abscopal tumor shrinkage in un-injected tumors, compared to 54% of patients in the G100+XRT arm.
• Patients in the combination arm demonstrated a greater increase of CD8 T cells within the tumors, as compared to the G100+XRT arm.
• The safety profile continues to appear favorable when compared to recently approved therapies for patients with relapsed/recurrent disease.
“These are exciting new data that provide stronger translational and clinical benefit profiles of our CMB305 and G100 therapeutic candidates in important forms of cancer where unmet need persists,” said Carlos Paya, M.D., Chief Executive Officer of Immune Design. “Armed with these findings, we look forward to beginning a Phase 3 pivotal clinical trial midyear 2018 to investigate CMB305 as a maintenance therapy in synovial sarcoma patients - an important step in our goal to provide a new treatment option to this patient population. In addition, these new G100 data give us greater confidence in the promise of this novel therapy in follicular lymphoma, and the potential to expand into other tumors.”
Upcoming Presentation and Conference Call
Senior management is scheduled to present at the upcoming Cowen & Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 9:00 a.m. Pacific Time/12:00 p.m. Eastern Time in Boston, as well as host a webcast and conference call at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time on March 14, 2018 to discuss fourth quarter and year end 2017 financial results. A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm, and an archive of each presentation will be available on the company website for at least 30 days. The March 14, 2018 live conference call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 3777048.
_____________________________________________
IMDZ
Out ALT @ $1.59 after lowering ask. So frustrating to trade. Level II of no value. Of concern is the failure of company to announce time/date for the quarterly which is estimated to be on the 12th as I find an issue since can't trade PM or AM. (They have announced investor presentations)
ALT
FWIW, I rarely make comments when not currently invested in a stock; keeps me more honest and appeases my conscience. Hence my statements of when I enter and leave.
NVTA
Back in ALT @ $1.48. Have sat on $1.45 bid for many days but never got filled. Want to be here for the data, but not sure if want to be in for the financials ("Mar 12, 2018 Q4 2017 Altimmune Inc Earnings Release (Estimated)").
ALT
Sold @ $90.50 to take profits. Has moved nicely and possibly more upside, but market too volatile. (also was without power all weekend and it was off briefly a short time ago so don't want to not be able to trade).
INCY
Out at $6.85 at EOD for a loss. Approaching overbought (already is on the CCI(20) and Wm%R(14)) and volume is drying up, especially today when bios are up big.
NVTA
Out @ $3.85 for ~$100 loss. See that has gone higher (unbelievable) but have already had 2 internet outages due to the extreme weather and didn't want to risk.
Will likely buy back next week.
SNOA
Now know that some folks got early tip regarding the offering. Bottom now seems set.
SNOA
In @ $10.80. Hope the Ring deal is not that significant.
From The Fly:
________________________________________________________
ADT, AMZN 08:27 Amazon deal for Ring doesn't disrupt core thesis on ADT, says Morgan Stanley Morgan Stanley analyst Toni Kaplan said Amazon's (AMZN) reported agreement to buy connected-doorbell and video camera startup Ring doe not disrupt her core thesis on ADT Inc. (ADT), which is centered on the latter's brand awareness and service differentiating it from intense competition from technology and DIY competitors. While the Ring deal increases Amazon's penetration into home automation, many of the newer products and services in this space go after a different subset of customers than ADT's core client base, according to Kaplan. However, she does acknowledge that a greater risk could result if Amazon adds professional monitoring or pulls its existing Alexa integration with ADT. Kaplan keeps her Overweight rating and $18 price target on ADT Inc. shares, which closed yesterday down 4.6% at $11.60 and are pointing to about a 2% further decline in pre-market trading.
Read more at:
https://thefly.com/landingPageNews.php?id=2691421
_________________________________________________________
ADT
Invitae expands existing credit facility to provide up to $40.0 million in available growth capital
SAN FRANCISCO, Feb. 27, 2018 /PRNewswire/ --
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has reached an agreement with Oxford Finance, LLC to expand its existing loan and security agreement by $20.0 million, bringing the total remaining capital available under the agreement to $40.0 million. This increase in net borrowing ability provides additional financial flexibility in 2018 as Invitae seeks to grow the size and scope of its genome network.
Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
Invitae received gross proceeds of $40.0 million from the first tranche of the credit facility upon closing in March 2017 and currently has an additional $20.0 million in capital available at its discretion. The amendment to the agreement provides an additional $20.0 million that may be funded at Invitae's option during the second quarter 2018. The loan matures in March 2022. The Company's obligations under the Loan and Security Agreement are subject to quarterly covenants to achieve certain volume and revenue levels as well as additional covenants, with the remaining terms of the amendment substantially similar to the original agreement.
About Invitae
Invitae Corporation (NYSE: NVTA) is bringing comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. As one of the fastest growing genetic information companies, Invitae is advancing the broad potential of genetics, helping to expand its use across the healthcare continuum. The company provides genetic information services for all stages of life – from preconception screening, to newborn diagnosis, to inherited disease screening, to proactive health management – and a unique, rapidly expanding network of patients, hospital systems, and advocacy partners that is moving genetics from one-dimensional testing to complex information management. For more information visit www.invitae.com, or follow us on Twitter, Facebook or LinkedIn.
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to grow the size and scope of its genome network. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; risks associated with the company's limited experience with respect to acquisitions; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's inability to raise additional capital on acceptable terms; risks associated with the company's ability to use rapidly changing genetic data to interpret test results accurately, consistently, and quickly; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Contact:
Kate McNeil
ir@invitae.com
347-204-4226
Cision View original content with multimedia:http://www.prnewswire.com/news-releases/invitae-expands-existing-credit-facility-to-provide-up-to-400-million-in-available-growth-capital-300605104.html
SOURCE Invitae Corporation
Copyright 2018 PR Newswire
All in all pretty good day considering. Keeping the little run going. Thought was going to really run out the gate this morning, didn't you.
NVTA
Out of SNOA for a time @ $4.58 -- will re-enter. You made a great buy. Saw Nasdaq buying shares almost all day @ $4.31/$4.32 and never selling.
SNOA
Thankfully it is. Held through the earning which I usually don't so missed some trading opportunities especially since it is in a Etrade account that doesn't allow pre- and post hours trading. Good luck.
Bullish Fool article from a couple of days ago:
_________________________________________________
3 Top Small-Cap Stocks to Buy in February
Motley Fool
Maxx Chatsko, The Motley Fool
Motley FoolFebruary 23, 2018
The American stock market -- alongside many of its international peers -- has been on fire in recent years, with the S&P 500 delivering total returns of nearly 22% in 2017. Of course, there were some signs that the market was a little overheated and overdue for at least a brief cooldown. That's exactly what investors are witnessing in February.
The sharp volatility in early 2018 is a stunning departure from last year, which was unusual for its lack of major movements -- up or down. But for long-term investors, there's not a whole lot to worry about. The recent pullback could even be a great time to dust off your watchlist in search of buying opportunities. I think genetic testing leader Invitae (NYSE: NVTA), enzyme designer Codexis (NASDAQ: CDXS), and urban cement powerhouse U.S. Concrete (NASDAQ: USCR) are among the top small-cap stocks to buy this month.
Growth compensating for dilution
Invitae has taken the genetic testing market, which helps clinicians and patients identify health risks or pinpoint disease diagnoses, by storm. Rather than selling ultra-expensive tests in low volumes, the company's business model relies on selling affordable tests in large volumes. Essentially, the goal is to greatly expand the market by making genetic testing accessible to just about any individual -- and it's worked so far, with some caveats.
In early January, the company provided investors with preliminary full-year 2017 results and preliminary full-year 2018 guidance. The stock promptly sank nearly 14%. Why? Wall Street was expecting more optimistic guidance for the year ahead. Analysts actually had good reason to be upset. But the stock was punished once again when earnings were finalized, despite the numbers actually being slightly better than the preliminary announcement.
The company achieved year-over-year revenue growth of 172%, but Invitae has been growing so quickly that that's considered a disappointment. The real dismay was prompted by preliminary guidance for the current year. While management forecasts at least $120 million in total revenue, or growth of 79% from 2017, Wall Street was expecting considerably higher sales in 2018 given two recent acquisitions.
However, individual investors don't have to follow Wall Street's lead and pretend that they aren't impressed with the incredible growth being delivered. Even better for long-term investors: With an astounding 30% drop thus far in 2018, Invitae could be a buy right now.
Still, it's not all lollipops and rainbows for the loss-accruing, high-growth company. For instance, there's a very long way to go before the business is profitable. Additionally, management relied on heavy dilution to fuel growth in recent years, which really sapped returns. But even after accounting for that, the company's market cap is now under $340 million for the first time since late 2016 -- a year in which the business coughed up $25 million in revenue. Compare that to at least $120 million expected in the year ahead on considerable growth in testing volume sales, product offerings, and collaborations with biopharma companies and, well, the stock is a comparative bargain given its high-growth credentials.
If you're looking for a hyper-growth stock gobbling up market share in a futuristic industry, then look no further than Invitae. Just be ready for higher-than-average volatility.
_________________________________________
https://finance.yahoo.com/news/3-top-small-cap-stocks-125600815.html
NVTA
Gotta agree with you. Good luck. Such a frustrating stock to trade with the small number of outstanding shares. Always a wide spread between bid-ask and generally Nasdaq is the MM on both ends. The Level II may show there are 100 shares on either bid or ask and when the trade is made there might be 1000's of shares which are traded. From where? I guess the best thing to do is not watch and hope for the best.
I believe Dan Ward who knows the stock well has a big position at a much higher level:
________________________________________
Daniel Ward, CFA
?
@danwardbio
Feb 1
More
(2/2) When saw $SNOA in 4.70s while $SNOAW 0.44 x 0.45, felt SNOA/SNOAW ratio off a bit so trimmed off 10% of my $SNOAW at 0.44. Will likely look to add more $SNOA tomorrow in 4.70s.
________________________________________
SNOA
Back in at $4.28 for a short term trade. MMs still doing same thing. They just took about 8000 shares (approx 30% of daily volume) at $$4.46 and then immediately dropped the ask down to $4.40. This one sure requires patience.
SNOA
No, are you? It has done really well.
Because of the recent volatility, been concentrating on low cap, low float bios many which don't have active boards. Trying to catch low bid in the am and be out in the pm or shortly thereafter; so haven't been posting much.
THC
Nope, was watching but let it get away about 5 days ago. It has been impressive. Positive 6 of the last 7 days despite the overall market volatility. Congrats!
PSTG
So glad sold @ $89.10 yesterday toward the EOD. Analyst's darling and Baker Bro big holding but not the street favorite. Thought they had good quarterly, but something is amiss. Has been a personal loss despite buying down.
INCY
Sold mid-day @ $60.90. Great bounce along with overall biotech sector.
CLVS
Sold INO @ $4.63 at the EOD, took profits. The news while good doesn't seem like it will have lasting effect although the finish was strong.
INO
The Wistar Institute Awarded More Than $1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology
PHILADELPHIA—(Jan. 18, 2018)—The Wistar Institute is pleased to announce it has been awarded a $1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA-based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.
Wistar will collaborate with Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health on this research effort.
Currently, RTS,S (Mosquirix™) is the only malaria vaccine that has moved through phase III trials, delivering modest protection for the populations most at risk. The vaccine also requires four doses and decreases in effectiveness over time providing partial protection. This issue of durability of protection as well as limited group protection supports the need to develop second generation vaccine candidates.
Incorporating Weiner’s and collaborators’ more than 25 years of research in design and delivery of synthetic DNA vaccines, the team’s goal is to generate a new vaccine that drives robust antigen-specific antibody and T cell immune responses. The Weiner Lab helped to found the field of nucleic acid vaccines and was the first to move DNA vaccines to clinical studies, establishing their safety and immunogenicity and opening up the field of DNA vaccines for clinical development.
“DNA vaccines have a significant public health potential to rapidly impact emerging pandemics, as this technology has conceptual safety, development, speed of production, field stability, and deliverability advantages for vaccine and immunotherapy development,” said Weiner. “These synthetic DNA approaches can be developed for important infectious diseases, and with our collaborators, we have shown this consistently by rapidly engineering multiple synthetic DNA vaccines and advancing them to clinical study with positive outcomes of safety and immune potency.”
Funding from the Bill & Melinda Gates Foundation will enable this team to adapt the technology to produce a synthetic DNA vaccine encoding antigens of Plasmodium (P.) faliciparum, the micro-organism that causes malaria. This strategy instructs the vaccine recipient to produce the antigen in his/her own body so that the immune system can be activated and mount a rapid and potent response against malaria. Fidel Zavala, M.D., professor in the Bloomberg School’s Department of Microbiology and Immunology and senior member of the Johns Hopkins Malaria Research Institute, will be responsible for testing the vaccine in animal models. Inovio Pharmaceuticals, Inc. will bring improved vaccine delivery and production know-how with their advanced CELLECTRA® electroporation delivery device that generates small, directional electric currents into the skin to facilitate optimal vaccine uptake, production of the antigen, and generation of relevant immune responses.
“We are excited to participate in this novel collaboration with the Wistar team, with the support of the Bill & Melinda Gates Foundation, focusing on synthetic DNA and Cellectra EP,” said Laurent Humeau, Ph.D., Senior VP of Research & Development, Inovio Pharmaceuticals, Inc. “The continued advancement of Cellectra Technology for synthetic DNA delivery, in this case against the malaria parasite, builds on our platform’s versatility, flexibility of design, ease of manufacturing, stability, reproducible clinical immune potency, and safety advantages compared to more traditional development platforms for vaccines.”
Malaria is a leading cause of death in infants and children in sub-Saharan Africa, including Malawi, Ghana and Kenya, as well as other developing areas of the world. A complex disease caused by a mosquito bite, the malaria parasite is able to evade the immune system and enter the bloodstream and eventually migrate to the liver where it establishes infection. There are four common strains of malaria, though P. falciparum is the most severe strain and is prevalent in Africa. A global disease burden, malaria accounted for 216 million cases worldwide and 445,000 deaths in 2016.
# # #
The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology, infectious diseases and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
________________________________________
wistar.org/news/press-releases/wistar-institute-awarded-more-14-million-create-malaria-vaccine-through
INO
In @ $7.80 on a major sell-off this past week.
Baker Bros 15th largest holding:
NVTA HEALTH CARE 7,288,300 $ 68,292,000 0.55% 0.61% 17 No Change 0% N/A Q1 2015 13F 2017-09-30 2017-11-14
(however, only 0.55% of their portfolio)
https://whalewisdom.com/filer/baker-bros-advisors-llc#/tabholdings_tab_link
NVTA
1/12/2018 HC Wainwright Set Price Target Buy $13.00
INO
Good buy. I sold far too soon. Not very familiar with the stock and I never anticipated the increase by Shanda Group would power it so much. Probably should have since it was down so much. I think I'll wait til the dust settles.
CYH
Sold @ $4.30, but can see it has more legs than thought. Look to re-enter.
CYH
Shanda Group Increases Investment in Community Health Systems and Expresses Support for Company
January 11, 2018 07:45 AM Eastern Time
FRANKLIN, Tenn. & MENLO PARK, Calif.--(EON: Enhanced Online News)--
On January 11, 2018, members of Shanda Group filed an amendment to Shanda’s Schedule 13D with the Securities and Exchange Commission to disclose an increase in its investment in Community Health Systems (NYSE: CYH). Shanda, together with its affiliates, is CYH’s largest shareholder and holds approximately 24.0% of the Company’s outstanding common stock.
“We have consistently maintained a good relationship with CYH and are supportive of the Company and its management team as they continue to execute on the Company’s strategic objectives.”
Robert Chiu, group president of Shanda Group, stated, “We have consistently maintained a good relationship with CYH and are supportive of the Company and its management team as they continue to execute on the Company’s strategic objectives.”
Wayne T. Smith, chairman and chief executive officer of the Company, stated, “We are pleased with Shanda’s continued support and welcome and value the input of Shanda and all of our stockholders.”
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. The Company, through its subsidiaries, owns, leases or operates 127 affiliated hospitals in 20 states with an aggregate of approximately 21,000 licensed beds. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
About Shanda Group
Shanda Group is a private investment firm involved in public market, private equity and real estate investments around the world. Shanda Group was founded in 1999 and was one of the earliest and leading Internet conglomerates in China. Its parent company, Shanda Interactive Entertainment Limited, completed its IPO in 2004 and was the first Chinese online game company successfully listed on NASDAQ. Committed to bringing positive changes to the world, Shanda Group actively supports philanthropic efforts with a particular focus on fundamental research for brain science.
For more information on Shanda’s Schedule 13D/A filing, please visit www.sec.gov.
Forward-Looking Statements
Statements contained in this news release regarding potential transactions, operating results, and other events are forward-looking statements that involve risk and uncertainties. Actual future events or results may differ materially from these statements. Readers are referred to the documents filed by Community Health Systems, Inc. with the Securities and Exchange Commission, including the Company’s annual report on Form 10-K, current reports on Form 8-K and quarterly reports on Form 10-Q. These filings identify important risk factors and other uncertainties that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Community Health Systems, Inc.
Investor Contact:
Thomas J. Aaron, 615-465-7000
Executive Vice President and Chief Financial Officer
or
Ross W. Comeaux, 615-465-7012
Vice President – Investor Relations
or
Media Contact:
Tomi Galin, 615-628-6607
Senior Vice President, Corporate Communications, Marketing and Public Affairs
or
Shanda Group
Jason Reindorp, 650-656-9574
Head of Global PR & Communications
__________________________________________________
CYH
How Incyte’s Jakafi Performed in 3Q17
By Mike Benson
Jan 9, 2018 | 9:23 AM
Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.
Chart - 005 (click link below for chart)
The chart above compares the revenues for Jakafi over the last few quarters.
Jakafi and its importance
Incyte’s team sells the drug Jakafi in US markets, while the development and commercialization rights for Jakafi are licensed to Novartis (NVS) outside US markets. Novartis markets Jakafi under the brand name Jakavi outside US markets.
Jakafi is the first oral JAK inhibitor approved by the FDA, and it’s also the first drug approved by the FDA from Incyte’s portfolio. Jakafi’s patent rights for the composition of matter and the use of the drug are valid up to November 2026, and Incyte has also received an extension on these patents up to late 2027.
Jakafi’s revenue
In 3Q17, Jakafi saw revenue of $303.9 million compared to $223.9 million in 3Q16 resulting from its strong sales in US markets. For the first nine months of 2017 (which ended on September 30, 2017), Jakafi brought in revenue of $831.0 million. Analysts expect Jakafi’s sales to cross $1.0 billion in 2017.
Incyte reported royalty revenue of $41.3 million from Novartis for Jakavi sales in 3Q17. For the first nine months of 2017, its royalty revenue from Novartis was $104.0 million.
(click link below for chart)
The iShares S&P 500 Growth ETF (IVW) holds 15.5% of its total investments in healthcare companies. IVW holds 0.1% in Incyte, 1.7% in Johnson & Johnson (JNJ), 0.8% in Pfizer (PFE), and 0.6% in Amgen (AMGN).
6
Incyte’s Collaborations and Developments in 4Q17
By Mike Benson
Jan 9, 2018 | 9:23 AM
Incyte’s Jakafi and its collaborations
Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the country through its own network.
However, outside US markets, the company has entered into an agreement with Novartis to develop and commercialize Jakafi. Novartis sells Jakafi under the name Jakavi, and Incyte receives royalties on Jakavi’s total sales.
Chart - 006 (click link below for chart)
The chart above compares Incyte’s royalty revenues and contract revenues over the last few quarters.
Recent developments
A few recent developments for Incyte include the following:
On December 10, 2017, Incyte released the 208-week (or four-year) follow-up data for its RESPONSE Study, a Phase 3 study evaluating Jakafi (ruxolitinib) for the treatment of patients with polycythemia vera who are resistant to hydroxyurea. The data show the durability of the response of Jakafi in treating polycythemia vera.
On November 15, 2017, Incyte announced the initiation of the RESET study, a double-blind, randomized, double-dummy pivotal study evaluating Jakafi in comparison to anagrelide in treating patients with essential thrombocythemia.
On October 31, 2017, Incyte announced the expansion of its collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN), to evaluate the efficacy and safety of Incyte’s epacadostat with AstraZeneca’s Imfinzi (durvalumab) for the treatment of patients with locally advanced non-small cell lung cancer.
On October 25, 2017, Incyte announced its collaboration with MacroGenics (MGNX) for MGA012, the investigational monoclonal antibody developed by MacroGenics. While Incyte received the exclusive worldwide rights for developing and commercializing MGA012 for all indications, MacroGenics retained the right to develop its pipeline in combination with MGA012.
________________________________________________
http://marketrealist.com/2018/01/incytes-collaborations-developments-4q17
INCY
Was thinking the same. Hope this will pass soon and buyers return for its value.
Still plenty of upside:
Consensus Rating: Buy
Consensus Rating Score: 2.79
Ratings Breakdown:
0 Sell Rating(s)
5 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $141.59
Price Target Upside: 40.34% upside
_______________________________________
https://www.marketbeat.com/stocks/NASDAQ/INCY/
INCY
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
By GlobeNewswire, January 09, 2018, 08:00:00 AM EDT
Advances development of Inovio's ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches
Engages the Parker Institute's extensive immunotherapy expertise and academic and research network on studies that have the potential to address cancers with high unmet needs
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology. The goal of the partnership is to design innovative studies that have the potential to address cancers with high unmet need. The initial trial under consideration between Inovio and the Parker Institute would address muscle invasive bladder cancer with INO-5401 in combination with checkpoint inhibitors and immune modulators.
Under the agreement, the Parker Institute will have responsibility for clinical study execution, working in collaboration with its established network of the most pre-eminent clinical academic and industry cancer centers. Based on Parker's novel approach to accelerating studies of cancer immunotherapies, Inovio will provide financial contributions if Inovio's product(s) studied under the collaboration reaches the initiation of a Phase 3 study.
The collaboration with Inovio represents the Parker Institute's first agreement within the field of DNA-based Immunotherapeutics. Inovio will benefit from the Parker Institute's innovative research model which brings together top academic cancer institutions and companies to share resources, data, and technology, accelerate research through unifying and managing clinical trial design, and conduct multi-center clinical trials.
Dr. J. Joseph Kim, Inovio's President and CEO, said, "We thank the Parker Institute for their confidence in our technology. This partnership aligns with our goal to address cancer with our ASPIRE™ immunotherapies. Through the Parker Institute's unique business model, Inovio will be able to work with university research pioneers and combination oncology therapy partners while leveraging the Institute's unique capabilities and expertise."
"This collaboration between the Parker Institute and Inovio exemplifies the mission of the Parker Institute for Cancer Immunotherapy to unlock the promise of immunotherapy by rapidly progressing next generation treatments into clinical trials," said Fred Ramsdell, PhD, Vice President, Research, Parker Institute for Cancer Immunotherapy. "If this collaboration leads to better cancer patient responses to immunotherapy, this would mark an important milestone for the field."
In addition to the work with the Parker Institute, Inovio also is collaborating to advance two immuno-oncology products through late-stage development for treatment of HPV-related cancers, advanced bladder cancer, and GBM. The products are being studied in combination with checkpoint inhibitors, in collaboration with Medimmune, Genentech, and Regeneron respectively.
About Inovio's ASPIRE™Immunotherapy Technology Platform
Inovio is advancing the medical potential of a unique class of immunotherapy technology. Its ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapies platform, which is the foundation for all of Inovio's products is unique in its ability to leverage the body's naturally existing mechanisms to generate robust, highly targeted immune responses to prevent and treat disease - and to do so in the body without harmful side effects. Its SynCon® immunotherapy design and CELLECTRA® delivery transform novel genetic blueprints into functional antibody and killer T cell responses. Inovio was the first to report the activation - in the body - of significant, antigen-specific functional T cells correlated to statistically significant efficacy in a placebo-controlled, randomized, double-blind phase 2b clinical trial (HPV-related pre-cancer), with a very favorable safety profile. These data were published in The Lancet and independently described as a "major breakthrough" in the field by U.S. National Cancer Institute scientists. Inovio has achieved significant antigen-specific immune responses against multiple diseases and is advancing a growing pipeline of cancer and infectious disease immunotherapies and vaccines.
About Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians and industry partners to build a smarter and more coordinated cancer immunotherapy research effort.
The Parker Institute is an unprecedented collaboration between the country's leading immunologists and cancer centers. The program started by providing institutional support to six academic centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. Recently, the institute also initiated programmatic support for top immunotherapy investigators, including a group of researchers at Dana-Farber Cancer Institute, Robert Schreiber, Ph.D., of Washington University School of Medicine in St. Louis, Nina Bhardwaj, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai and Phil Greenberg, M.D., of the Fred Hutchinson Cancer Research Center.
The Parker Institute network also includes more than 40 industry collaborations, more than 60 labs and more than 300 of the nation's top researchers focused on treating the deadliest cancers.
The goal is to accelerate the development of breakthrough immune therapies capable of turning most cancers into curable diseases. The institute was created through a $250 million grant from The Parker Foundation.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, and the sufficiency of our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, our Form 10-Q for the period ended September 30, 2017, and other regulatory filings we make from time to time. There can be no assurance that any product candidate in Inovio's pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Inovio undertakes no obligation to update or revise these statements, except as may be required by law.
CONTACTS:
Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com
Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com
Source: Inovio Pharmaceuticals, Inc.
____________________________________________________
INO